Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
Conditions: COVID-19; Liver Disease; Vaccine Reaction Intervention: Sponsors: Hepatopancreatobiliary Surgery Institute of Gansu Province; LanZhou University; Huashan Hospital; The Sixth People's Hospital of Shenyang City; Xingtai City People's Hospital; Jinchang Central Hospital; Baoding People's Hospital; The Third People's Hospital of Zhenjiang City; Shanxi Bethune Hospital; Wuhan Jinyintan Hospital; Jincheng People's Hospital; The Third People's Hospital of Tibet Autonomous Region; People's Hospital of Ningxia Hui Autonomous Region; Fuling Central Hospital of Chongqing City; Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region; The Central Hospital of Lishui City; The Third People's Hospital of Linfen City; Yibin First People's Hospital; Jingzhou Central Hospital; Wuxi Fifth People's Hospital; Qingyang People's Hos pital; The First Affiliated Hospital of Anhui Medical University; Beilun Hospital of Traditional Chinese Medicine; Henan Provincial People's Hospital; Qingdao Sixth People's Hospital; The First Affiliated Hospital of Xiamen University; Shandong Provincial Hospital; Beijing YouAn Hospital; The First People's Hospital of Taicang; Taiyuan Third People's Hospital; Tianjin Second People's Hospital; Tianjin Third Central Hospital; Qishan Hospi...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: COVID-19 | Government | Hospitals | Liver | Liver Disease | Research | Urology & Nephrology | Vaccines